These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 37709918

  • 1. Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.
    Baker JG, Shaw DE.
    Handb Exp Pharmacol; 2024; 285():369-451. PubMed ID: 37709918
    [Abstract] [Full Text] [Related]

  • 2. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.
    Chung KF, Caramori G, Adcock IM.
    Eur J Clin Pharmacol; 2009 Sep; 65(9):853-71. PubMed ID: 19557399
    [Abstract] [Full Text] [Related]

  • 3. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M, Till D, Stenglein S, Singh D, Krummen M.
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [Abstract] [Full Text] [Related]

  • 4. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    Sin DD, Man SF.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):28-35. PubMed ID: 16457807
    [Abstract] [Full Text] [Related]

  • 5. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
    Prescrire Int; 2016 Nov 08; 25(176):272-277. PubMed ID: 30715829
    [Abstract] [Full Text] [Related]

  • 6. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease.
    Page C, Cazzola M.
    Eur Respir J; 2014 Aug 08; 44(2):475-82. PubMed ID: 24696121
    [Abstract] [Full Text] [Related]

  • 7. ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
    Matera MG, Cazzola M.
    Drugs; 2007 Aug 08; 67(4):503-15. PubMed ID: 17352511
    [Abstract] [Full Text] [Related]

  • 8. β2 Agonists.
    Billington CK, Penn RB, Hall IP.
    Handb Exp Pharmacol; 2017 Aug 08; 237():23-40. PubMed ID: 27878470
    [Abstract] [Full Text] [Related]

  • 9. Beta-adrenoceptor responses of the airways: for better or worse?
    Broadley KJ.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):15-27. PubMed ID: 16469310
    [Abstract] [Full Text] [Related]

  • 10. Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease.
    Prenner BM.
    Expert Opin Pharmacother; 2007 Dec 08; 8(17):3069-84. PubMed ID: 18001266
    [Abstract] [Full Text] [Related]

  • 11. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.
    Craig SS, Dalziel SR, Powell CV, Graudins A, Babl FE, Lunny C.
    Cochrane Database Syst Rev; 2020 Aug 05; 8(8):CD012977. PubMed ID: 32767571
    [Abstract] [Full Text] [Related]

  • 12. [Recent advances in study of long β(2)-adrenoceptor agonist].
    Ge XY, Mo YM, Pan L, Cheng MS.
    Yao Xue Xue Bao; 2016 Dec 05; 51(12):1838-44. PubMed ID: 29908535
    [Abstract] [Full Text] [Related]

  • 13. Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.
    Zafar MA, Droege C, Foertsch M, Panos RJ.
    Expert Opin Investig Drugs; 2014 Dec 05; 23(12):1687-701. PubMed ID: 25139313
    [Abstract] [Full Text] [Related]

  • 14. Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma.
    Buhl R, Farmer SG.
    Proc Am Thorac Soc; 2004 Dec 05; 1(2):136-42. PubMed ID: 16113426
    [Abstract] [Full Text] [Related]

  • 15. β2-agonist therapy in lung disease.
    Cazzola M, Page CP, Rogliani P, Matera MG.
    Am J Respir Crit Care Med; 2013 Apr 01; 187(7):690-6. PubMed ID: 23348973
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological management of asthma.
    McDonald C, Lipp J.
    Aust Fam Physician; 1998 Apr 01; 27(1-2):64-8, 70. PubMed ID: 9503709
    [Abstract] [Full Text] [Related]

  • 17. Research and development of bronchodilators for asthma and COPD with a focus on G protein/KCa channel linkage and β2-adrenergic intrinsic efficacy.
    Kume H, Fukunaga K, Oguma T.
    Pharmacol Ther; 2015 Dec 01; 156():75-89. PubMed ID: 26432616
    [Abstract] [Full Text] [Related]

  • 18. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
    Beeh KM, Beier J.
    Adv Ther; 2009 Jul 01; 26(7):691-9. PubMed ID: 19609496
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
    Pelaia G, Muzzio CC, Vatrella A, Maselli R, Magnoni MS, Rizzi A.
    Expert Opin Pharmacother; 2015 Jul 01; 16(13):2009-21. PubMed ID: 26194120
    [Abstract] [Full Text] [Related]

  • 20. Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.
    Gao J, Pleasants RA.
    Int J Chron Obstruct Pulmon Dis; 2015 Jul 01; 10():775-89. PubMed ID: 25926729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.